MedTrace Logo

Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy

NCT05662410 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-31

No results posted yet for this study

Summary

In the present study, investigators attempt to evaluate the short-term, detailed changes in choroidal morphology after three monthly injections of aflibercept in pachychoroid neovasculopathy. The association between these changes and clinical outcomes will be additionally investigated. The primary purpose of this study is to provide reference data regarding the aflibercept-related morphologic changes that implicate structural and functional choroidal alteration, and hence its clinical implications.

Conditions

  • Pachychoroid Neovasculopathy

Interventions

DRUG

Three monthly injections of intravitreal aflibercept

Three monthly intravitreal injection of aflibercept (2.0mg / 0.05ml) after diagnosis of pathychoroid neovasculopathy.

Sponsors & Collaborators

  • Nune Eye Hospital, Seoul, Korea

    collaborator OTHER

  • HanGil Eye Hospital

    collaborator OTHER

  • Kim's Eye Hospital

    lead OTHER

Principal Investigators

  • Jae Hui H Kim, M.D. · Kim's Eye Hospital, South Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-26
Primary Completion
2024-05-24
Completion
2024-05-26

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05662410 on ClinicalTrials.gov